NOBEL MEDICUS, vol.9, no.2, pp.57-62, 2013 (SCI-Expanded)
Objective: In this study treatment response of 201 chronic hepatitis B (CHB) patients to 245 mg/day tenofovir disoproxil fumarate (TDF) was evaluated upon 48th week of treatment.